PPIB and hydrops fetalis: In the DAPA‐HF trial, in which the primary composite end point was cardiovascular death or worsening heart failure, Docherty et al found consistent benefits of dapagliflozin by use/nonuse or dose of a variety of background heart failure treatments, including diuretics, RAAS inhibitors, and β‐adrenergic antagonists in patients with heart failure with reduced ejection fraction.7